Vyome Holdings Reports 76% Revenue Decline and Increased Net Loss for Six Months Ended June 30, 2026

Vyome Holdings, Inc. reported a significant decline in financial performance for the six months ended June 30, 2026, with total revenue of $58,546, a decrease of approximately 76% compared to $248,535 in the same period of 2025. The company attributed this drop primarily to a lack of milestone payments and reduced sales from its product lines, particularly from its licensing agreement with Sun Pharma, which generated no milestone fees in the current period compared to $116,900 in the previous year. The cost of goods sold also decreased to $30,243 from $69,881, resulting in a gross profit of $28,303, down from $178,654.

Operating expenses surged to $2,020,809, up from $701,839 in the prior year, driven largely by increased research and development costs, which rose to $1,173,128 from $170,329. This increase reflects the company's focus on advancing its lead product, VT-1953, a topical gel for treating malignant fungating wounds, as it prepares for pivotal clinical trials. General and administrative expenses also rose significantly, totaling $842,466 compared to $525,019 in the previous year, reflecting higher legal and professional fees associated with being a public company.

The company reported a net loss of $1,705,204 for the six months ended June 30, 2026, compared to a net loss of $602,732 for the same period in 2025. The loss attributable to owners of the company was $1,648,466, with a loss per share of $(0.24) based on a weighted average of 6,855,306 shares outstanding. The increase in net loss was attributed to higher operating expenses and the absence of significant revenue from product sales.

In terms of operational developments, Vyome Holdings has been actively pursuing its clinical programs, including the submission of an Orphan Drug Designation application for VT-1953 to the FDA in January 2026. The company also entered into an in-licensing agreement with Impetis Biosciences Limited for preclinical JAK inhibitor assets, which could provide future revenue streams through royalties. As of June 30, 2026, the company had cash and cash equivalents of $7,887,510, a significant increase from $4,982,333 at the end of 2025, primarily due to proceeds from an at-the-market (ATM) offering.

Looking ahead, Vyome Holdings anticipates continued operational challenges as it seeks to advance its clinical programs while managing its financial resources. The company has indicated that it will need to secure additional funding to support its ongoing operations and product development efforts. Management remains focused on cost management and is exploring various financing options, including equity offerings and strategic partnerships, to ensure the sustainability of its operations in the coming months.